Neurosense Therapeutics is trading 9.76% higher at $2.70, with no confirmed company-specific catalyst for the October 26, 2026 move. - The latest verified company announcement was an October 19 patent filing concerning PrimeC’s potential use in traumatic brain injury, which predates the rise. - The October 26 Alzheimer’s biomarker item appears to repeat earlier findings rather than document a new announcement. - The S&P 500 was up 0.57% and Nasdaq Composite up 0.82%; the supportive market backdrop may have contributed, but the available evidence does not establish the cause of this stock move.